NCT00874328View on ClinicalTrials.gov

A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

Irinotecan

Irinotecan iv D1 q 3 weeks until maximum 6 cycles

DRUG

Cisplatin

cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles

DRUG

TS-1 (S-1)

TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV

NCT00874328 - A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter